TSH Biopharm Corporation Limited   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Taipei Taiwan (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2007
NCT01375322
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

TSH Biopharm Corporation Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Albuminuria (Phase 4)

Angina Pectoris (Phase 3)

Angina, Stable (Phase 3)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Essential Hypertension (Phase 4)

Hypertension (Phase 4)

Hypotension (Phase 3)

Hypotension, Orthostatic (Phase 3)

Spondylitis (Phase 3)

Spondylitis, Ankylosing (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 12